文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

2型糖尿病对重度主动脉瓣狭窄患者主动脉瓣置换前后心肌结构与功能的影响

Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis.
PubMed 文献 · Circulation · 2023-09-25

研究纳入95例无冠心病、等待主动脉瓣置换的重度主动脉瓣狭窄患者(30例合并2型糖尿病,65例不合并),并以30名健康志愿者和30例无主动脉瓣狭窄的2型糖尿病患者为对照。结果显示,合并2型糖尿病的主动脉瓣狭窄患者在瓣膜置换前心肌能量代谢(PCr/ATP)和血管舒张应激心肌血流量更差;置换后不合并糖尿病者上述指标恢复正常,而合并糖尿病者持续异常,收缩功能和临床指标亦无改善。

要点

  • 合并2型糖尿病的重度主动脉瓣狭窄患者,瓣膜置换前心肌能量代谢和应激心肌血流量更差。
  • 主动脉瓣置换可使不合并2型糖尿病者的PCr/ATP、应激心肌血流量和收缩功能恢复正常。
  • 合并2型糖尿病者瓣膜置换后心肌能量代谢持续异常,收缩功能和临床指标未见改善。

核心结论

  • 重度主动脉瓣狭窄合并2型糖尿病患者在主动脉瓣置换后仍存在心肌PCr/ATP、血管舒张应激心肌血流量和心脏收缩功能的持续异常。
  • 不合并2型糖尿病的重度主动脉瓣狭窄患者,主动脉瓣置换可有效使心肌PCr/ATP、血管舒张应激心肌血流量和心脏收缩功能恢复正常。

研究设计与样本

  • 研究为前瞻性病例对照研究,纳入95例无冠心病、等待主动脉瓣置换的重度主动脉瓣狭窄患者,其中30例合并2型糖尿病、65例不合并(平均年龄71岁,95%CI 69–73;女性34例,占37%)。
  • 对照组为30名人口学匹配的健康志愿者和30例无主动脉瓣狭窄的2型糖尿病患者;采用磷磁共振波谱和心血管磁共振评估。
  • 主动脉瓣狭窄患者在瓣膜置换前1个月和置换后6个月评估心脏PCr/ATP、腺苷应激心肌血流量、整体纵向应变、NT-proBNP和6分钟步行距离;2型糖尿病对照在基线和6个月随访接受相同评估;健康志愿者仅评估一次且不做6分钟步行试验。

主要发现

  • 瓣膜置换前,重度主动脉瓣狭窄患者(合并与不合并2型糖尿病合计)的PCr/ATP低于健康志愿者(健康志愿者2.15[95%CI 1.89, 2.34];主动脉瓣狭窄1.66[1.56, 1.75];P<0.0001)。
  • 瓣膜置换前,重度主动脉瓣狭窄患者的血管舒张应激心肌血流量低于健康志愿者(健康志愿者2.11 mL min g[1.89, 2.34];主动脉瓣狭窄1.54 mL min g[1.41, 1.66];P<0.0001)。
  • 瓣膜置换前,在主动脉瓣狭窄组内,合并2型糖尿病患者的PCr/ATP低于不合并者(不合并2型糖尿病1.74[1.62, 1.86];合并2型糖尿病1.44[1.32, 1.56];P=0.002)。
  • 瓣膜置换前,在主动脉瓣狭窄组内,合并2型糖尿病患者的血管舒张应激心肌血流量低于不合并者(不合并2型糖尿病1.67 mL min g[1.5, 1.84];合并2型糖尿病1.25 mL min g[1.22, 1.38];P=0.001)。
  • 瓣膜置换前,合并2型糖尿病的主动脉瓣狭窄患者PCr/ATP低于无主动脉瓣狭窄的2型糖尿病对照(合并2型糖尿病1.44[1.30, 1.60];2型糖尿病对照1.66[1.56, 1.75];P=0.04),血管舒张应激心肌血流量亦更低(1.25 mL min g[1.10, 1.41]对1.54 mL min g[1.41, 1.66];P=0.001)。

临床怎么用

  • 对重度主动脉瓣狭窄合并2型糖尿病且拟行主动脉瓣置换者,应认识到瓣膜置换后心肌能量代谢、应激心肌血流量和收缩功能可能持续异常,需加强术后心功能随访与综合管理。
  • 对不合并2型糖尿病的重度主动脉瓣狭窄患者,主动脉瓣置换后心肌能量代谢、应激心肌血流量和收缩功能可望恢复正常。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 2 diabetes (T2D) is associated with an increased risk of left ventricular dysfunction after aortic valve replacement (AVR) in patients with severe aortic stenosis (AS). Persistent impairments in myocardial energetics and myocardial blood flow (MBF) may underpin this observation. Using phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance, this study tested the hypothesis that patients with severe AS and T2D (AS-T2D) would have impaired myocardial energetics as reflected by the phosphocreatine to ATP ratio (PCr/ATP) and vasodilator stress MBF compared with patients with AS without T2D (AS-noT2D), and that these differences would persist after AVR. METHODS: Ninety-five patients with severe AS without coronary artery disease awaiting AVR (30 AS-T2D and 65 AS-noT2D) were recruited (mean, 71 years of age [95% CI, 69, 73]; 34 [37%] women). Thirty demographically matched healthy volunteers (HVs) and 30 patients with T2D without AS (T2D controls) were controls. One month before and 6 months after AVR, cardiac PCr/ATP, adenosine stress MBF, global longitudinal strain, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and 6-minute walk distance were assessed in patients with AS. T2D controls underwent identical assessments at baseline and 6-month follow-up. HVs were assessed once and did not undergo 6-minute walk testing. RESULTS: Compared with HVs, patients with AS (AS-T2D and AS-noT2D combined) showed impairment in PCr/ATP (mean [95% CI]; HVs, 2.15 [1.89, 2.34]; AS, 1.66 [1.56, 1.75]; P<0.0001) and vasodilator stress MBF (HVs, 2.11 mL min g [1.89, 2.34]; AS, 1.54 mL min g [1.41, 1.66]; P<0.0001) before AVR. Before AVR, within the AS group, patients with AS-T2D had worse PCr/ATP (AS-noT2D, 1.74 [1.62, 1.86]; AS-T2D, 1.44 [1.32, 1.56]; P=0.002) and vasodilator stress MBF (AS-noT2D, 1.67 mL min g [1.5, 1.84]; AS-T2D, 1.25 mL min g [1.22, 1.38]; P=0.001) compared with patients with AS-noT2D. Before AVR, patients with AS-T2D also had worse PCr/ATP (AS-T2D, 1.44 [1.30, 1.60]; T2D controls, 1.66 [1.56, 1.75]; P=0.04) and vasodilator stress MBF (AS-T2D, 1.25 mL min g [1.10, 1.41]; T2D controls, 1.54 mL min g [1.41, 1.66]; P=0.001) compared with T2D controls at baseline. After AVR, PCr/ATP normalized in patients with AS-noT2D, whereas patients with AS-T2D showed no improvements (AS-noT2D, 2.11 [1.79, 2.43]; AS-T2D, 1.30 [1.07, 1.53]; P=0.0006). Vasodilator stress MBF improved in both AS groups after AVR, but this remained lower in patients with AS-T2D (AS-noT2D, 1.80 mL min g [1.59, 2.0]; AS-T2D, 1.48 mL min g [1.29, 1.66]; P=0.03). There were no longer differences in PCr/ATP (AS-T2D, 1.44 [1.30, 1.60]; T2D controls, 1.51 [1.34, 1.53]; P=0.12) or vasodilator stress MBF (AS-T2D, 1.48 mL min g [1.29, 1.66]; T2D controls, 1.60 mL min g [1.34, 1.86]; P=0.82) between patients with AS-T2D after AVR and T2D controls at follow-up. Whereas global longitudinal strain, 6-minute walk distance, and NT-proBNP all improved after AVR in patients with AS-noT2D, no improvement in these assessments was observed in patients with AS-T2D. CONCLUSIONS: Among patients with severe AS, those with T2D demonstrate persistent abnormalities in myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function after AVR; AVR effectively normalizes myocardial PCr/ATP, vasodilator stress MBF, and cardiac contractile function in patients without T2D.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Jex N, Greenwood JP, Cubbon RM, et al. Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis. Circulation. 2023. PMID: 37746744. doi:10.1161/CIRCULATIONAHA.122.063444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。